Status:
UNKNOWN
Efficacy and Safety of Raltegravir (RAL) in Treatment-experienced HIV-1 Infected Adult Chinese Patients
Lead Sponsor:
Shanghai Public Health Clinical Center
Conditions:
HIV
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
To assess the safety, tolerability and efficacy of Raltegravir (RAL) when combined with other antiretroviral drugs in treatment-experienced Chinese HIV-infected patients, including those with multi-dr...
Detailed Description
An open, prospective, uncontrolled pilot study to evaluate the efficacy and safety of raltegravir in treatment-experienced HIV-1 infected adult patients who have failed the previous antiretroviral tre...
Eligibility Criteria
Inclusion
- HIV-infected patients aged over 18 who have failed previous antiretroviral treatment with multi-drug resistant or with multi-drug intolerance
Exclusion
- The patient is aged below 18 or over 65 years
- The patient has serious opportunistic infections or tumors
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2012
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01201239
Start Date
September 1 2010
End Date
October 1 2012
Last Update
September 14 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Public Health Clinical Center
Shanghai, Shanghai Municipality, China, 201508